Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
81,000
Employees81,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
81,000
Employees81,000

PFE Key Statistics

Market cap
147.15B
Market cap147.15B
Price-Earnings ratio
14.66
Price-Earnings ratio14.66
Dividend yield
6.84%
Dividend yield6.84%
Average volume
47.51M
Average volume47.51M
High today
$25.89
High today$25.89
Low today
$25.25
Low today$25.25
Open price
$25.57
Open price$25.57
Volume
55.26M
Volume55.26M
52 Week high
$27.69
52 Week high$27.69
52 Week low
$20.92
52 Week low$20.92

Stock Snapshot

With a market cap of 147.15B, Pfizer(PFE) trades at $25.83. The stock has a price-to-earnings ratio of 14.66 and currently yields dividends of 6.8%.

On 2026-01-16, Pfizer(PFE) stock moved within a range of $25.25 to $25.89. With shares now at $25.83, the stock is trading +2.3% above its intraday low and -0.2% below the session's peak.

Trading volume for Pfizer(PFE) stock has reached 55.26M, versus its average volume of 47.51M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.

PFE News

Simply Wall St 7h
Has The Market Overlooked Pfizer After The Post‑Pandemic Reset?

If you are wondering whether Pfizer's current share price fairly reflects its fundamentals, you are not alone. This article is designed to help you weigh that u...

Has The Market Overlooked Pfizer After The Post‑Pandemic Reset?
TipRanks 17h
Pfizer Advances Prazosin Manufacturing Shift With New Bioequivalence Study

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools f...

TipRanks 17h
Pfizer’s TOFAst Real-World Study in Ulcerative Colitis: What Investors Should Watch

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools f...

Analyst ratings

57%

of 28 ratings
Buy
39.3%
Hold
57.1%
Sell
3.6%

More PFE News

Sherwood News 2d
Big Pharma enters 2026 with an appetite for deals

At the JPMorgan Healthcare Conference, biotechs and Big Pharma signaled they’re primed for M&A this year, after a big year for deals in 2025. Revolution Medici...

Big Pharma enters 2026 with an appetite for deals
TipRanks 2d
Pfizer Advances CGRP Migraine Asset With New Bioequivalence Study

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Pfizer Tests New Migraine Drug Formulation in Early-Stage...

TipRanks 2d
Pfizer Completes Key China Phase 3 Trial for Migraine Drug Rimegepant

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools f...

Nasdaq 2d
PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock

Pfizer PFE stock has declined almost 5% in a month, losing $7.3 billion in market capitalization. Shares dipped recently after the company announced its financi...

PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock
Simply Wall St 2d
Should Pfizer’s Oncology Win And Obesity Push Require Action From Pfizer Investors?

Earlier this week, Pfizer used the ASCO Gastrointestinal Cancers Symposium to share positive BREAKWATER trial data for its BRAFTOVI® combination in BRAF V600E m...

Should Pfizer’s Oncology Win And Obesity Push Require Action From Pfizer Investors?
TipRanks 3d
Pfizer Ends Mid-Stage Lupus Skin Trial, Trimming a Small but Promising Autoimmune Option

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools f...

TipRanks 3d
Pfizer: Underappreciated Growth Story Driven by Oncology, Obesity Pipeline, and Post-LOE Recovery Prospects

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer and keeping the price target at $30.00. Claim 70% Off TipRanks Premium Unlock hedge fu...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .